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Intention-to-treat analysisIntroduction
Trials that randomly allocate participants to groups tend to
produce groups with similar characteristics, especially when many
participants are randomised.1 Because the groups have similar
characteristics, their outcomesarealsoexpected tobe similar. If only
one of the groups then receives an intervention, the difference in
outcomes between the groups can therefore be attributed to that
intervention. If each group receives a unique intervention, the
difference in outcomes between the groups instead reﬂects the
difference in the effects of the two interventions.2 Before recruit-
ment of participants into a clinical trial begins, the ﬁnal protocol for
the trial should be agreed upon by all the investigators, approved by
anethics committee, and registered ona publicly available register.3
Ideally, the trial is thenconducted exactlyaccording to thatprotocol,
with all participants who were randomised receiving all doses of
their allocated intervention and undergoing all scheduledmeasure-
ment procedures.4 Unfortunately, the conduct ofmany clinical trials
deviates from the protocol, to some degree, which can introduce
unwanted systematic differences (ie, bias) between the groups after
randomisation.
The ﬁrst two sections of this ResearchNote describe two types of
deviations fromtheprotocol: thosewhere the intended intervention
is not received, and those where the intended measurements are
notmade. The third sectiondescribes amethod of analysing thedata
known as intention-to-treat analysis,which is designed tominimise
the bias caused by some of these deviations from the protocol.
Intention-to-treat analysis involves analysing participants accord-
ing to their initial groupallocation (ie, randomisation) andnotby the
treatment they actually receive. The ﬁnal section explains how
intention-to-treat analysis can be easily incorporated into physio-
therapy trials.
Protocol deviations in which participants do not receive their
allocated intervention
Poor tolerance
Some interventions may not be fully tolerated by people with a
particular characteristic. Sometimes it is easy to see the link, such
as a localised reaction to strapping tape5 or fainting during tilt
table standing for neurorehabilitation.6 However, it is not always
clear whether there is a link. For example, in a trial involving
people with spinal cord injury, one participantmissed some sitting
balance training sessions due to an exacerbation of his back pain,7
which may or may not have been due to the training. Regardless of
the relationship between the intervention and the intolerance,
such gaps in the intended treatment schedule could bias the trial’s
estimate of the effect of the intervention.
Poor adherence
Even if an intervention is perfectly tolerable, some participants
may not adhere to some (or all) of their allocated intervention byhttp://dx.doi.org/10.1016/j.jphys.2015.05.013
1836-9553/ 2015 Australian Physiotherapy Association. Published by Elsevier B.V. Alchoice, perhaps because the allocated intervention is perceived as
ineffective or the study is given low priority in the participant’s
schedule. Adherence to the intervention may also be incomplete if
participants forget doses. In trials of physiotherapy interventions,
there may be additional reasons such as that the intervention is too
exhausting, confronting or boring.7–9 Although rare, participants
may even receivemore than the intended amount of intervention.10
Use of other interventions
Some participants may use interventions other than those they
were allocated – either instead of, or in addition to, their allocated
intervention – perhaps because they are dissatisﬁed with their
allocated intervention or with their clinical progress. Some may
even use the intervention that has been allocated to another
group in the trial. For example, in a trial of exercise versus no
intervention, participants in the control group may feel that they
are missing out and independently decide to start the exercises
explained in the consent form for the trial.11 This could occur part
way through the trial or for the whole intervention period.
Investigator error
On rare occasions, an investigator may accidentally allocate a
participant to a group that was not the group dictated by the
randomisation process. For example, in a trial of dynamic splints for
distal radial fracture,12 an allocationwas eithermisreadormisheard
and one participant received the wrong intervention. Alternatively,
an investigator may recruit a person who does not meet the
eligibility criteria for the trial, either by applying the eligibility
criteria incorrectly or by more information about the participant
becoming available after randomisation.13 When ineligible people
aremistakenly randomised, itmaybepossible to exclude them from
the intention-to-treat analysis without adding bias, as long as there
are few cases and the decision to remove participants is adjudicated
by a committee blinded to treatment.14
Protocol deviations in which participants do not undergo
scheduled measurements
Not all participants who enter a clinical trial complete all of the
scheduled measurements. For example, participants may be unco-
operative15,16 or too busy to attend outcome measurement.15
Others may not tolerate their allocated intervention and falsely
believe that further measurement of their outcome data will give
unhelpful data or will expose their lack of adherence. In trials with
long follow-up, some participants may emigrate, making them
unavailable to complete the measurements, despite willingness to
continue. In trials involving elderly or seriously ill people, some
participants may die before completing the study.17 Because the
outcomes of these participants are not measured, these all
constitute loss to follow-up.
Sometimes the reason for loss to follow-up may seem strongly
relatedto the intervention. Imaginea trial inwhich theexperimentall rights reserved.
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severity that typically occurs over time in the disease of interest.
With increases in symptom severity, many participants in the
control group might fail to attend follow-up visits because their
symptomsare toosevere for themto leavehome. It iseasy toseehow
only measuring the remaining participants in the control group
could introduce bias – that is, the only participants who contribute
follow-up data for the control group are those with unrepresenta-
tively mild symptom severity. This could prevent the analysis from
identifying that the intervention reduces symptom severity.
Conversely, the reason for loss to follow-up may seem random
and unrelated to the intervention. As an example, consider
participants who change their work hours and can no longer attend
scheduled measurement visits, such as occurred in a trial of neural
tissue management of neck pain.18 If this were truly random loss to
follow-up, it would reduce the power of the study but not introduce
bias. However, causes that seem unrelated may be subtly and
systematically related to the intervention. For example, the
participants may have chosen to increase their work hours because
their symptoms had improved. Without outcome data for these
participants, it is impossible to assess whether their absence
introduces bias. Therefore, regardless of the reason that participants
are lost to follow-up, wemust assume that the absence of their data
from the analysis can bias the estimate of the effect of the
intervention.
Intention-to-treat analysis
An intention-to-treat analysis of a clinical trial includes all data
that can be obtained from each participant and analyses each
participant’s data in the group to which that participant was
randomised, regardless of whether that participant received the
allocated intervention.19–22 To demonstrate this, imagine a con-
trolled trial of stretches before swimming training sessions to
prevent foot and calf cramps in 100 male swimmers. All available
data from each swimmer that was originally randomised to the
stretching group would be analysed in that group, including
swimmers who did only some (or even none) of the stretches.
Similarly, all available data from swimmers who were originally
allocated to not stretch would be analysed in the control group,
including any who undertook stretching. Even if a swimmer from
either group undertook additional interventions that were not part
of the trial, his data would still be analysed in the group towhich he
was originally randomised.
Why is intention-to-treat analysis recommended?
Intention-to-treat analysis may seem counter-intuitive to some
readers who think it is more appropriate to analyse participants
according to what intervention they actually received. For
example, if swimmers were meant to stretch but they didn’t, it
may seem more appropriate to analyse their data in the control
group (and vice versa). It may seem appropriate to exclude
swimmers who undertook additional interventions. Such an
analysis would provide some indication of the efﬁcacy of the
intervention.23 Efﬁcacy refers to the effect of an intervention when
it is administered exactly as intended, which often requires highly
controlled experimental conditions to eliminate real-world factors
(such as a swimmer forgetting or running out of time to do the
stretches, in the hypothetical example). Determining the efﬁcacy
of an intervention can be an interesting question, and some
authors may choose to include such an analysis in a trial.24
Ultimately, however, the clinical usefulness of any intervention
depends on its effectiveness; that is, whether it has an effect when
applied in everyday clinical practice where factors such as poor
adherence potentially reduce its effect.23 Therefore, it is arguably
more important that clinical trials include an intention-to-treat
analysis.Assessing effectiveness (as opposed to efﬁcacy) is not the only
advantage of the intention-to-treat approach. Another advantage
is that groups that were similar due to randomisation are
prevented from becoming unbalanced by unequal loss to follow-
up. As an example, assume in our hypothetical trial of stretching
before swimming training that 20 participants are highly
motivated and competitive, 60 have average motivation and
20 are lazy. Because the trial is randomised, the groups are likely to
be similar at baseline – with roughly 10 motivated, 30 average and
10 lazy swimmers in each group. During the trial, most swimmers
do their allocated intervention (stretching or no stretching).
However, half of the lazy swimmers in the stretching group decide
not to bother stretching. If wewere to swap these ﬁve swimmers to
the control group, the control group would have 15 lazy swimmers
and the experimental group would have only ﬁve. This is
sometimes called an ‘as treated’ analysis. Differences in the group
outcomes would become very difﬁcult to interpret. Perhaps lazy
swimmers don’t try hard enough during training to cause a cramp,
whichwould spuriously reduce the trial’s estimate of the beneﬁt of
stretching. Conversely, perhaps lazy swimmers are less ﬁt and
thereforemore prone to cramps, whichmight exaggerate the trial’s
estimate of the beneﬁt of stretching. Even if we could measure
laziness accurately, we don’t know enough about the relationship
between laziness and cramps to knowwhat the effect of swapping
participants might be. Even if there is no effect on cramps, stacking
the control groupwith lazy swimmers could still affect a secondary
outcome like a time trial. Another alternative, known as ‘per
protocol’ analysis, is to omit participants from the analysis if
they did not receive the allocated treatment, but this can create
similar problems of imbalanced groups. Overall, messing with the
balanced groups created by randomisation is likely to introduce
unmeasurable and unpredictable bias. Intention-to-treat analysis
avoids this problem by preserving the original groups.
Doesn’t intention-to-treat analysis underestimate the
intervention’s effect?
If some randomised participants receive the intervention
opposite to their intended intervention, then intention-to-treat
analysis will produce a more conservative estimate of an effective
experimental intervention’s effect (ie, the between-groupdifference
will be smaller in magnitude). However, to analyse participants by
what intervention they undertook risks introducing other biases,
such as disrupting the balance ofmotivated and lazy participants, as
discussed above. Crucially, these biases are of unknown direction
andmagnitude,making it impossible to interpret the result obtained
with conﬁdence. At least the bias from intention-to-treat analysis is
in a known direction, so readers can be conﬁdent that if a signiﬁcant
effect is observed then the ﬁnding is not spurious and itmay evenbe
conservative. Therefore, intention-to-treat analysis is preferable to
the alternative.
Are there any alternatives to intention-to-treat analysis?
There are many techniques for estimating effects of treatment
(as distinct from effects of allocation) in clinical trials with non-
compliance. These methods attempt to preserve the exchange-
ability of groups generated by randomisation. For an introduction
see the paper by Stuart and colleagues.25 When certain conditions
aremet, thesemethods provide unbiased estimates of the effects of
treatment. Nonetheless, the primary analysis of clinical trials, at
least pragmatic randomised trials, should probably be an inten-
tion-to-treat analysis of the effects of allocation.
Applying intention-to-treat analysis in physiotherapy research
For many trials of physiotherapy interventions, the published
report neither mentions nor demonstrates that intention-to-treat
analysis was undertaken. In 2011, only 18% of all trials on the
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were rated as having used intention-to-treat analysis.26 Trials
can fail to meet this criterion by not using intention-to-treat
analysis, by not reporting that intention-to-treat analysis was
used, or by misinterpreting the deﬁnition of intention-to-treat
analysis. A study of trials published in 1997 showed varied
compliance with the deﬁnition.23 However, since the CONSORT
Statement27 and key publications about intention-to-treat analysis
were published,20,21 there has been improved reporting of the
information required for readers to interpret whether analysis was
by intention to treat in physiotherapy trial reports.26
The low prevalence of use of intention-to-treat analysis in
physiotherapy trials is disappointing because analysing data in
this way only requires two simple steps. First, participants who
discontinue their allocated intervention for any reason must be
encouraged to undergo the remaining planned outcome measure-
ment, if at all possible. Brieﬂy explaining to these participants the
importance of obtaining the data may assist in gaining their
consent for ongoing data collection. Second, the statistical analysis
of whatever data can be obtained must leave the participants’ data
in the groups created by the random allocation process. Of course,
for readers to know that intention-to-treat analysis was used, a
crucial third step is to indicate in the published report that these
two steps were taken.
Minimising poor adherence and loss to follow-up
Some causes of poor adherence and loss to follow-up can be
minimised by carefully planning who enrols into the trial and how
investigators maintain contact with them.Missing data can also be
minimised by early checking for missing or invalid data and
retrieving the data retrospectively, where valid and possible.
Regular audits from an external researcher during the course of the
trial may be helpful. To the extent that the researchers can
maximise adherence and follow-up, they will reduce the potential
for intention-to-treat analysis to underestimate the effect of the
intervention.
Is imputation ofmissing data part of intention-to-treat analysis?
The original papers about intention-to-treat analysis did not
recommend imputation ofmissing data.19–21 This is also the stance
of the Cochrane Handbook,22 the CONSORT statement,27 and the
PEDro Scale (http://www.pedro.org.au/wp-content/uploads/
PEDro_scale.pdf), which describe intention-to-treat analysis as
simply collecting data from each participant, wherever available,
and analysing the data in that participant’s original group,
regardless of what intervention they received. Imputation of data
can be performed alongside an intention-to-treat analysis,28
although readers should have more conﬁdence in the imputed
data when logical assumptions about the missing data can be
made.6
Does complete follow-up guarantee intention-to-treat analysis?
If the published report of a clinical trial states that all
participants were followed up and the ﬁnal group sizes are thesame as those thatwere randomly generated, readers often assume
that intention-to-treat analysis has been conducted. However, the
researchers may have swapped equal numbers of participants
between the groups – perhaps due to adherence issues. This is why
the explanatory notes for tools such as the PEDro Scale specify that
a study should only be accepted as having used intention-to-treat
analysis if: the published report states that the analysis was by
‘intention to treat’ and does not provide any evidence that
participants were excluded unnecessarily; or the published report
states that all available participants were analysed in the groups to
which they were originally randomised.26
Summary
Researchers conducting a clinical trial should ﬁrst strive to
ensure thateachparticipantadheres to the interventionas randomly
allocatedandundergoesall theplannedmeasurementsofoutcomes.
However, when a participant does not receive the intervention as
intended, ongoing participation in all the plannedmeasurements of
outcomes should be encouraged. Whatever data can be obtained
should then be included in the analysis, with each participant’s
data being retained in the group to which that participant was
originally randomised. Readers of reports of clinical trials should
take some reassurance from the use of intention-to-treat analysis,
especially when other information in the paper is consistent with
such an analysis having been undertaken.
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